3 completed, 3 recruiting, 2 terminated, 2 unknown. 5 Phase 2, 2 Not applicable, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Unknown 2, Active not recruiting 1, Completed 1, Recruiting 1 |
| Not applicable | 2 | Completed 1, Terminated 1 |
| Phase 3 | 1 | Completed 1 |
Follow Barwon Health: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Telacebec (T) Treatment in Adults With Buruli Ulcer (BU). (TREAT BU) Telacebec - Buruli Ulcer | Phase 2 | Recruiting | Barwon Health | 200 | 2024-07-09 | 2026-06-30 |
| National Robotics-Assisted Radical Prostatectomy Database Database, Prostate Cancer | Recruiting | Melbourne Health | 10000 | 2024-07-01 | 2024-08-26 | |
| Treatment Of Newly-diagnosed Follicular Lymphoma With CELMoD Golcadomide, Rituximab +/- Nivolumab. golcadomide, Nivolumab 10 MG/ML, Rituximab - Follicular Lymphoma Stage II, Follicular Lymphoma Stage III | Phase 2 | Active not recruiting | Olivia Newton-John Cancer Research Institute | 40 | 2023-08-31 | 2026-10-16 |
| The EXCEL Registry of Patients Requiring ECMO Critically Ill, Acute Respiratory Failure | Recruiting | Australian and New Zealand Intensive Care Research Centre | 3000 | 2019-02-01 | 2023-09-15 | |
| The Vitamin C, Hydrocortisone and Thiamine in Patients With Septic Shock Trial Vitamin C, Thiamine, Hydrocortisone, - Shock, Septic, Critically Ill | Phase 2 | Completed | Australian and New Zealand Intensive Care Research Centre | 216 | 2018-05-02 | 2019-10-10 |
| A Feasibility Study Of NAB-Paclitaxel In Combination With Carboplatin As First Line Treatment Of Gastrointestinal Neuroendocrine Carcinomas NAB paclitaxel, Carboplatin - Gastrointestinal Neuroendocrine Carcinomas | Phase 2 | Unknown | Barwon Health | 4 | 2015-05-01 | 2017-11-22 |
| IST Neoadjuvant Abraxane in Newly Diagnosed Breast Cancer Nab-Paclitaxel - Breast Cancer | Phase 2 | Unknown | Barwon Health | 60 | 2013-04-01 | 2017-07-02 |
| A Feasibility Trial Using Lithium As A Neuroprotective Agent In Patients Undergoing Prophylactic Cranial Irradiation For Small Cell Lung Cancer Lithium - Small Cell Lung Cancer | Not applicable | Terminated | Barwon Health | 7 | 2012-11-01 | 2015-03-18 |
| A Pilot Study to Assess the Follow-up of Prostate Cancer Patients Who Have Undergone Radiotherapy Treatment Prostate Cancer | Terminated | Barwon Health | 107 | 2007-10-01 | 2017-02-02 | |
| Bisphosphonate and Anastrozole Trial - Bone Maintenance Algorithm Assessment Alendronate sodium - Breast Cancer | Phase 3 | Completed | Barwon Health | 303 | 2005-09-01 | 2013-03-13 |
| Thyroid-Associated Ophthalmopathy Subtypes and Orbital Antibodies Carbimazole, radio-active iodine (I131) - Graves' Ophthalmopathy | Not applicable | Completed | Barwon Health | 60 | 2003-08-01 | 2007-02-02 |
Breast Neoplasms (2) · Critical Illness (2) · Prostatic Neoplasms (2) · Buruli Ulcer (1) · Graves Ophthalmopathy (1) · Heart Arrest (1) · Lymphoma, Follicular (1) · Pathologic Complete Response (1) · Sepsis (1) · Shock, Septic (1) · Small Cell Lung Carcinoma (1) · Ulcer (1) · Vasoplegia (1)
Albumin-Bound Paclitaxel (2) · 130-nm albumin-bound paclitaxel (1) · Alendronate (1) · Ascorbic Acid (1) · Carbimazole (1) · Carboplatin (1) · Hydrocortisone (1) · Iodine-131 (1) · Lithium (1) · Nivolumab (1) · Rituximab (1) · Taxes (1) · Thiamine (1) · telacebec (1)
Australia (11) · New Zealand (2) · Brazil (1)
Mustafa Khasraw, MD (3) · Carol L Hodgson, PhD (1) · Daniel O'Brien, MD (1) · Eliza Hawkes, MBBS (1) · Jack R Wall, BMBS, FRACP, PhD (1) · Karen White (1) · Nora Luethi, MD (1) · Rinaldo Bellomo, Professor (1) · Rodney Lynch, BMedSc, MBBS (1) · Tomoko Fujii, MD (1)
PMID 28869790, PMID 30763338, PMID 31142242, PMID 31950979, PMID 32389109, PMID 32705292, PMID 36174613, PMID 38979716, PMID 40298907, PMID 41212045, PMID 42163394